Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Jun;22(6):397-402.
doi: 10.1002/clc.4960220606.

The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy

Affiliations
Clinical Trial

The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy

K Jansson et al. Clin Cardiol. 1999 Jun.

Abstract

Background: The effects of treatment with captopril or metoprolol on heart rate variability (HRV) were investigated in 38 patients (29 men and 9 women) with mild to moderate symptoms of heart failure due to idiopathic dilated cardiomyopathy (DCM).

Hypothesis: The aim of the study was to investigate and compare the effects of the angiotensin-converting enzyme inhibitor captopril with those of the selective beta-adrenergic receptor blocker metoprolol on HRV in patients with idiopathic DCM.

Methods: Heart rate variability was analyzed in the time and frequency domains from 18th of Holter monitoring before randomized treatment was started, after 6 months of therapy, and 1 month after therapy was stopped.

Results: Captopril treatment increased HRV expressed as total power and low-frequency power in the frequency domain. There was no change in the time domain. In the metoprolol group, there was a pronounced increase in both time- and frequency-domain indices of HRV. The increase in total power was partly maintained 1 month after therapy was stopped in both treatment groups.

Conclusion: Treatment with captopril and metoprolol increases HRV in patients with DCM. This effect seems to be maintained for at least 1 month after therapy is stopped. The increase in HRV seems to be more pronounced with metoprolol, and the two different pharmacologic approaches may have additive effects that are of prognostic importance in patients with heart failure.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Pomeranz B, Macaulay RJ, Caudill MA, Kutz I, Adam D, Gordon D, Kilborn KM, Barger AC, Shannon DC, Cohen RJ: Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985; 248: H151–153 - PubMed
    1. Kjellgren O, Gomes J: Heart rate variability and baroreflex sensitivity in myocardial infarction. Am Heart J 1993; 125: 204–215 - PubMed
    1. Kleiger R, Miller J, Bigger J, Moss A: Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256–262 - PubMed
    1. Pipilis A, Flather M, Ormerod O, Sleight P: Heart rate variability in acute myocardial infarction and its association with infarct size and clinical course. Am J Cardiol 1991; 67: 1137–1139 - PubMed
    1. Farrell TG, Bashir Y, Cripps T, Malik M, Poliniecki J, Bennet ED, Bennett ED, Ward DE, Camm AJ: Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal‐average electrocardiogram. J Am Coll Cardiol 1991; 18: 687–697 - PubMed

MeSH terms

LinkOut - more resources